Human STAT1 Gain-of-Function Heterozygous Mutations: Chronic Mucocutaneous Candidiasis and Type I Interferonopathy.
Okada S, Asano T, Moriya K, Boisson-Dupuis S, Kobayashi M, Casanova JL, Puel A.
J Clin Immunol. 2020 Nov;40(8):1065-1081. doi: 10.1007/s10875-020-00847-x. Epub 2020 Aug 27.
Chronic mucocutaneous candidiasis.
Kirkpatrick CH.
Pediatr Infect Dis J. 2001 Feb;20(2):197-206. doi: 10.1097/00006454-200102000-00017.
[Chronic mucocutaneous candidiasis].
Hon-Balla B, Erdős M.
Orv Hetil. 2022 Jan 30;163(5):171-180. doi: 10.1556/650.2022.32409. Print 2022 Jan 30.
Chronic Mucocutaneous Candidiasis in Early Life: Insights Into Immune Mechanisms and Novel Targeted Therapies.
Shamriz O, Tal Y, Talmon A, Nahum A.
Front Immunol. 2020 Oct 16;11:593289. doi: 10.3389/fimmu.2020.593289. eCollection 2020.
Chronic mucocutaneous candidiasis: what can we conclude about IL-17 antagonism?
Veverka KK, Feldman SR.
J Dermatolog Treat. 2018 Aug;29(5):475-480. doi: 10.1080/09546634.2017.1398396. Epub 2017 Nov 21.
Chronic mucocutaneous candidiasis.
Kirkpatrick CH.
J Am Acad Dermatol. 1994 Sep;31(3 Pt 2):S14-7. doi: 10.1016/s0190-9622(08)81260-1.
Chronic mucocutaneous candidiasis.
Kirkpatrick CH.
Eur J Clin Microbiol Infect Dis. 1989 May;8(5):448-56. doi: 10.1007/BF01964059.
Chronic mucocutaneous candidiasis due to gain-of-function mutation in STAT1.
Carey B, Lambourne J, Porter S, Hodgson T.
Oral Dis. 2019 Apr;25(3):684-692. doi: 10.1111/odi.12881. Epub 2018 Jun 8.
Chronic mucocutaneous candidiasis.
Dwyer JM.
Annu Rev Med. 1981;32:491-7. doi: 10.1146/annurev.me.32.020181.002423.
Primary immunodeficiency and chronic mucocutaneous candidiasis: pathophysiological, diagnostic, and therapeutic approaches.
Egri N, Esteve-Solé A, Deyà-Martínez À, Ortiz de Landazuri I, Vlagea A, García AP, Cardozo C, Garcia-Vidal C, Bartolomé CS, Español-Rego M, Yiyi L, Bosch-Amate X, Ferrando J, Yagüe J, Juan M, Alsina L.
Allergol Immunopathol (Madr). 2021 Jan 2;49(1):118-127. doi: 10.15586/aei.v49i1.20. eCollection 2021.
